Summary
Colin Fischer is a doctoral candidate and translational cancer researcher with 12 years of laboratory and field experience focused on developing genetically engineered, induced pluripotent stem cell-derived NK cell therapies for blood cancers. He blends deep bench skills—complex tissue culture, genetic engineering, sequencing, and data science—with translational aims to create safer, off-the-shelf alternatives to chemotherapy and donor-derived products. His background spans mechanistic studies of drug resistance, CAR-T/BiTE engineering, and frontline genomics work during the COVID-19 pandemic, giving him a rare mix of therapeutic development and high-throughput diagnostics experience. Colin has also worked in ocean biogeochemistry, an unusual cross-disciplinary chapter that honed his experimental design and large-scale fieldwork capabilities. Based in Vienna and trained at UCL and the University of Minnesota, he emphasizes collaborative, ethically minded science and seeks to lower economic and geopolitical barriers to global research collaboration.
12 years of coding experience
4 years of employment as a software developer
Bachelor's of Science Biology, Bachelor's of Science Biology at University of Minnesota Duluth
Medical University of Vienna
University College London
Italian